These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 6447522)

  • 21. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
    Góra-Tybor J; Robak T; Warzocha K; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antitumor activity of macromomycin].
    Kato T; Yamanaka N; Katayama S; Mizutani M; Ota K
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1097-101. PubMed ID: 7184442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
    Gale GR; Atkins LM; Meischen SJ; Schwartz P
    Cancer Treat Rep; 1979 Mar; 63(3):449-56. PubMed ID: 427825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental study of the antimetastatic activity of thaliblastin].
    Mircheva I
    Eksp Onkol; 1984; 6(2):48-9. PubMed ID: 6096114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
    Walker EM; Gale GR
    Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093
    [No Abstract]   [Full Text] [Related]  

  • 26. [Studies on the antineoplastic action of N-methylisoindigotin].
    Ji XJ; Zhang FR; Liu Y; Gu QM
    Yao Xue Xue Bao; 1985 Apr; 20(4):247-51. PubMed ID: 4072694
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
    Kuśnierczyk H; Matuszyk J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(5-6):547-56. PubMed ID: 2487366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.
    Lake LM; Grunden EE; Johnson BM
    Cancer Res; 1975 Oct; 35(10):2858-63. PubMed ID: 808270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones.
    Li LH; DeKoning TF; Nicholas JA; Kramer GD; Wilson D; Wallace TL; Collins MJ
    Lab Anim Sci; 1987 Feb; 37(1):41-4. PubMed ID: 3035278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lewis lung carcinoma in mice as an experimental therapy model. II. The effect of BCNU, cyclophosphamide and/or surgery treatment on early and advanced tumor in mice.
    Budzyński W
    Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):373-7. PubMed ID: 7184488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Potentiation of the antitumor action of alkylating compounds by amphotericin B].
    Iaremenko KV; Eremeeva AA; Tereshin IM
    Antibiotiki; 1977; 22(2):153-8. PubMed ID: 404957
    [No Abstract]   [Full Text] [Related]  

  • 34. Complete regression of Lewis lung carcinoma by cyclophosphamide in combination with immunomodulators.
    Abe S; Takahashi K; Yamazaki M; Mizuno D
    Jpn J Cancer Res; 1985 Jul; 76(7):626-30. PubMed ID: 3928559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin A: failure to demonstrate in mice an anti-tumour effect, whether combined with cytotoxic drugs or not.
    Cattan A; Bresson ML
    Bull Cancer; 1986; 73(2):201-6. PubMed ID: 3730637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Captopril augments antitumor activity of cyclophosphamide in mice.
    Kowalski J; Herman ZS
    Pol J Pharmacol; 1996; 48(3):281-5. PubMed ID: 9112663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.
    Johnson RK; Houchens DP; Gaston MR; Goldin A
    Cancer Chemother Rep; 1975; 59(4):697-705. PubMed ID: 1175164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
    Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
    Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of two antiproteinases on the growth of transplantable tumors and the proliferation of untransformed and transformed cells in culture.
    Gavilondo J; Pérez R; Mainardi V; Lage A
    Neoplasma; 1982; 29(3):315-22. PubMed ID: 6182475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.